https://www.selleckchem.com/products/a939572.html
59; 95% CI, 1.17-2.15; = 0.003) and belimumab significantly increased the 36 Physical Component Summary (PCS) score (MD, 1.60; 95% CI, 0.30-2.90; = 0.02). Regarding adverse events, there was no significant difference between the belimumab group and the control group. The results suggest that belimumab plus standard therapy is more effective than placebo plus standard therapy in SLE patients. The results suggest that belimumab plus standard therapy is more effective than placebo plus standard therapy in SLE patients. It is unknown if foo